189 related articles for article (PubMed ID: 20369907)
1. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
Gardette V; Andrieu S; Lapeyre-Mestre M; Coley N; Cantet C; Ousset PJ; Grand A; Monstastruc JL; Vellas B
CNS Drugs; 2010 May; 24(5):431-42. PubMed ID: 20369907
[TBL] [Abstract][Full Text] [Related]
2. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.
Gardette V; Lapeyre-Mestre M; Piau A; Gallini A; Cantet C; Montastruc JL; Vellas B; Andrieu S;
CNS Drugs; 2014 Feb; 28(2):157-70. PubMed ID: 24408842
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Kröger E; van Marum R; Souverein P; Egberts T
Drugs Aging; 2010 Aug; 27(8):663-75. PubMed ID: 20658794
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Fisher A; Carney G; Bassett K; Chappell NL
Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
[TBL] [Abstract][Full Text] [Related]
5. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
6. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
[TBL] [Abstract][Full Text] [Related]
7. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
Nordström P; Religa D; Wimo A; Winblad B; Eriksdotter M
Eur Heart J; 2013 Sep; 34(33):2585-91. PubMed ID: 23735859
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Lanctôt KL; Herrmann N; Yau KK; Khan LR; Liu BA; LouLou MM; Einarson TR
CMAJ; 2003 Sep; 169(6):557-64. PubMed ID: 12975222
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial.
Campbell NL; Dexter P; Perkins AJ; Gao S; Li L; Skaar TC; Frame A; Hendrie HC; Callahan CM; Boustani MA
Trials; 2013 May; 14():125. PubMed ID: 23782591
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
O'Regan J; Lanctôt KL; Mazereeuw G; Herrmann N
J Clin Psychiatry; 2015 Nov; 76(11):e1424-31. PubMed ID: 26646039
[TBL] [Abstract][Full Text] [Related]
12. Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).
Fereshtehnejad SM; Johnell K; Eriksdotter M
Drugs Aging; 2014 Mar; 31(3):215-24. PubMed ID: 24497071
[TBL] [Abstract][Full Text] [Related]
13. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
Shahim B; Xu H; Haugaa K; Zetterberg H; Jurga J; Religa D; Eriksdotter M
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):128-136. PubMed ID: 38224338
[TBL] [Abstract][Full Text] [Related]
15. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
Charbonneau C; Massoud F; Dorais M; LeLorier J
Curr Med Res Opin; 2008 Dec; 24(12):3287-94. PubMed ID: 19032117
[TBL] [Abstract][Full Text] [Related]
17. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
Xu H; Garcia-Ptacek S; Jönsson L; Wimo A; Nordström P; Eriksdotter M
Neurology; 2021 Apr; 96(17):e2220-e2230. PubMed ID: 33741639
[TBL] [Abstract][Full Text] [Related]
18. Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
Johannsen P
CNS Drugs; 2004; 18(12):757-68. PubMed ID: 15377166
[TBL] [Abstract][Full Text] [Related]
19. A population-based study of cholinesterase inhibitor use for dementia.
Herrmann N; Gill SS; Bell CM; Anderson GM; Bronskill SE; Shulman KI; Fischer HD; Sykora K; Shi HS; Rochon PA
J Am Geriatr Soc; 2007 Oct; 55(10):1517-23. PubMed ID: 17697100
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
